Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Laria, JC; Aguilera-Morillo, MC; Alvarez, E; Lillo, RE; Lopez-Taruella, S; del Monte-Millan, M; Picornell, AC; Martin, M; Romo, J.

Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer

Mathematics. 2021; 9(3): Nº de citas: 3 [doi:10.3390/math9030222]

Ruiz-Pinto, S; Pita, G; Martin, M; Nunez-Torres, R; Cuadrado, A; Shahbazi, MN; Caronia, D; Kojic, A; Moreno, LT; de la Torre-Montero, JC; Lozano, M; Lopez-Fernandez, LA; Ribelles, N; Garcia-Saenz, JA; Alba, E; Milne, RL; Losada, A; Perez-Moreno, M; Benitez, J; Gonzalez-Neira, A.

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome

CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021; 109(2): 462-470 Nº de citas: 5 [doi:10.1002/cpt.2013]

Custodio-Cabello, S; Cabezon-Gutierrez, L; Palka-Kotlowska, M; Acebes, EO; Khosravi-Shahi, P.

Ant-EGFR Antibody Plus Chemotherapy Treatment in a Patient with Synchronous Merkel Cell Carcinoma and Colorectal Cancer

CUREUS JOURNAL OF MEDICAL SCIENCE. 2021; 13(1): [doi:10.7759/cureus.12916]

Schettini, F; Chic, N; Braso-Maristany, F; Pare, L; Pascual, T; Conte, B; Martinez-Saez, O; Adamo, B; Vidal, M; Barnadas, E; Fernandez-Martinez, A; Gonzalez-Farre, B; Sanfeliu, E; Cejalvo, JM; Perrone, G; Sabarese, G; Zalfa, F; Peg, V; Fasani, R; Villagrasa, P; Gavila, J; Barrios, CH; Lluch, A; Martin, M; Locci, M; De Placido, S; Prat, A.

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Npj Breast Cancer. 2021; 7(1): 1-1 Nº de citas: 460 [doi:10.1038/s41523-020-00208-2]

Gonzalez-Cao, M; Puertolas, T; Riveiro, M; Munoz-Couselo, E; Ortiz, C; Paredes, R; Podzamczer, D; Manzano, JL; Molto, J; Revollo, B; Carrera, C; Mateu, L; Fancelli, S; Espinosa, E; Clotet, B; Martinez-Picado, J; Cerezuela, P; Soria, A; Marquez, I; Mandala, M; Berrocal, A; Spanish Melanoma Grp GEM.

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Journal for ImmunoTherapy of Cancer. 2021; 9(3): Nº de citas: 12 [doi:10.1136/jitc-2020-001664]

Navarro S; Cuatrecasas M; Hernández-Losa J; Landolfi S; Musulén E; Ramón Y Cajal S; García-Carbonero R; García-Foncillas J; Pérez-Segura P; Salazar R; Vera R; García-Alfonso P.

Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Oncología Médica y de la Sociedad Española de Anatomía Patológica.

Revista Espanola de Patologia. 2021; 54(1): 41-54 [doi:10.1016/j.patol.2020.07.004]

Aparicio, J; del Muro, XG; Maroto, P; Terrasa, J; Castellano, D; Bastus, R; Guma, J; Sagastibeltza, N; Duran, I; Ochenduszko, S; Meana, JA; Garcia-Sanchez, J; Arranz, JA; Girones, R; Germa, JR.

Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(1): 58-64 Nº de citas: 9 [doi:10.1007/s12094-020-02393-9]

Garcia-Alfonso, P; Garcia-Gonzalez, G; Gallego, I; Peligros, MI; Ortega, L; Perez-Solero, GT; Sandoval, C; Martin, AM; Codesido, MB; Ferrandiz, AC; Martin, M.

Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(1): 122-129 Nº de citas: 3 [doi:10.1007/s12094-020-02402-x]

Lopez, MDG; Rodas, IM; Pujol, CA; Perez, AG; Saachez, EV; Alvarez, RA.

Simultaneous diagnosis of liver PEComa in a family with known Li-Fraumeni syndrome: a case report

Clinical Sarcoma Research. 2020; 10(1): Nº de citas: 7 [doi:10.1186/s13569-020-00143-7]

Fasching, PA; Beck, JT; Chan, A; De Laurentiis, M; Esteva, FJ; Jerusalem, G; Neven, P; Pivot, X; Bianchi, GV; Martin, M; Chandiwana, D; Lanoue, B; Ridol, A; Wang, YB; Lorenc, KR; Nusch, A.

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

BREAST. 2020; 54: 148-154 Nº de citas: 34 [doi:10.1016/j.breast.2020.09.008]

Molins, JB; Jimenez, JGD; Valderrama, BP; Echaburu, JAV; Hernando-Polo, S; Duran, MAC; Villa-Guzman, JC; Arija, JAA; Ostiategui, ML; Milagro, NL; Gonzalez-del-Alba, A; Gonzalez, BM; Diaz, EG; Gauna, DC; Santasusana, MD; Herranz, UA; Solans, XGD; Perez-Gracia, JL; Vazquez, JP; Morales-Barrera, R; Pous, AF.

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

CLINICAL GENITOURINARY CANCER. 2020; 18(6): 452-460 Nº de citas: 11 [doi:10.1016/j.clgc.2020.05.004]

Munoz-Unceta, N; Zugazagoitia, J; Manzano, A; Jimenez-Aguilar, E; Olmedo, ME; Cacho, JD; Oliveira, J; Domine, M; Ortega-Moran, L; Aguado, C; Luna, AM; Fernandez, L; Perez, J; Font, C; Salvador, C; Corral, J; Benitez, G; Ros, S; Biosca, M; Calvo, V; Martinez, J; Sanchez-Canovas, M; Lopez, R; Sereno, M; Mielgo, X; Aparisi, F; Carmona, M; Carrion, R; Ponce-Aix, S; Soares, M; Martinez-Salas, I; Garcia-Morillo, M; Juan-Vidal, O; Blasco, A; Munoz, AJ; Paz-Ares, L; Grp Trombosis & Canc SEOM.

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

EUROPEAN JOURNAL OF CANCER. 2020; 141: 193-198 Nº de citas: 22 [doi:10.1016/j.ejca.2020.10.002]

Rubio, VEC; Perez-Segura, P; Munoz, A; Farre, AL; Ruiz, LC; Lorente, JA.

High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score

THROMBOSIS RESEARCH. 2020; 196: 349-354 Nº de citas: 26 [doi:10.1016/j.thromres.2020.09.021]

Johnston, SRD; Harbeck, N; Hegg, R; Toi, M; Martin, M; Shao, ZM; Zhang, QY; Rodriguez, JLM; Campone, M; Hamilton, E; Sohn, J; Guarneri, V; Okada, M; Boyle, F; Neven, P; Cortes, J; Huober, J; Wardley, A; Tolaney, SM; Cicin, I; Smith, IC; Frenzel, M; Headley, D; Wei, R; San Antonio, B; Hulstijn, M; Cox, J; O'Shaughnessy, J; Rastogi, P; Behalf MonarchE Comm Members Inve.

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(34): Nº de citas: 698 [doi:10.1200/JCO.20.02514]

Gonzalez-del-Alba, A; Arranz, JA; Bellmunt, J; Maroto, JP; Fernandez-Calvo, O; Valderrama, BP; Gonzalez-Billalabeitia, E; Mendez-Vidal, MJ; Cassinello, J; Romero-Laorden, N; Climent, MA; Puentel, J; Pelaez, I; Lazaro-Quintela, M; Gallardo, E; Suarez, C.

Latest progress in molecular biology and treatment in genitourinary tumours

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(12): 2175-2195 [doi:10.1007/s12094-020-02373-z]

Cabezon-Gutierrez, L; Custodio-Cabello, S; Palka-Kotlowska, M; Oliveros-Acebes, E; Garcia-Navarro, MJ; Khosravi-Shahi, P.

Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data

CANCER TREATMENT REVIEWS. 2020; 90: Nº de citas: 21 [doi:10.1016/j.ctrv.2020.102102]

Ascierto, PA; Del Vecchio, M; Mandala, M; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, MO; Maio, M; Middleton, MR; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, A; Fecher, LA; Millward, M; Khushalani, NI; Queirolo, P; Lobo, M; de Pril, V; Loffredo, J; Larkin, J; Weber, J.

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

LANCET ONCOLOGY. 2020; 21(11): 1465-1477 Nº de citas: 414 [doi:10.1016/S1470-2045(20)30494-0]

Litton, JK; Hurvitz, SA; Mina, LA; Rugo, HS; Lee, KH; Goncalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roch, H; Im, YH; Eiermann, W; Quek, RGW; Usari, T; Lanzalone, S; Czibere, A; Blum, JL; Martin, M; Ettl, J.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

ANNALS OF ONCOLOGY. 2020; 31(11): 1526-1535 Nº de citas: 286 [doi:10.1016/j.annonc.2020.08.2098]